Literature DB >> 12761501

Large-scale identification and characterization of human genes that activate NF-kappaB and MAPK signaling pathways.

Akio Matsuda1, Yutaka Suzuki, Goichi Honda, Shuji Muramatsu, Osamu Matsuzaki, Yukiko Nagano, Takahiro Doi, Kunitada Shimotohno, Takeshi Harada, Eisuke Nishida, Hiroshi Hayashi, Sumio Sugano.   

Abstract

We have carried out a large-scale identification and characterization of human genes that activate the NF-kappaB and MARK signaling pathways. We constructed full-length cDNA libraries using the oligo-capping method and prepared an arrayed cDNA pool consisting of 150 000 cDNAs randomly isolated from the libraries. For analysis of the NF-kappaB signaling pathway, we introduced each of the cDNAs into human embryonic kidney 293 cells and examined whether it activated the transcription of a luciferase reporter gene driven by a promoter containing the consensus NF-kappaB binding sites. In total, we identified 299 cDNAs that activate the NF-kappaB pathway, and we classified them into 83 genes, including 30 characterized activator genes of the NF-kappaB pathway, 28 genes whose involvement in the NF-kappaB pathways have not been characterized and 25 novel genes. We then carried out a similar analysis for the identification of genes that activate the MARK pathway, utilizing the same cDNA resource. We assayed 145 000 cDNAs and identified 57 genes that activate the MARK pathway. Interestingly, 27 genes were overlapping between the NF-kappaB and the MAPK pathways, which may indicate that these genes play cross-talking roles between these two pathways.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12761501     DOI: 10.1038/sj.onc.1206406

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  159 in total

1.  CC2D1A is a regulator of ESCRT-III CHMP4B.

Authors:  Nicolas Martinelli; Bettina Hartlieb; Yoshiko Usami; Charles Sabin; Aurelien Dordor; Nolwenn Miguet; Sergiy V Avilov; Euripedes A Ribeiro; Heinrich Göttlinger; Winfried Weissenhorn
Journal:  J Mol Biol       Date:  2012-03-08       Impact factor: 5.469

2.  Genome-scale functional profiling of the mammalian AP-1 signaling pathway.

Authors:  Sumit K Chanda; Suhaila White; Anthony P Orth; Richard Reisdorph; Loren Miraglia; Russell S Thomas; Paul DeJesus; Daniel E Mason; Qihong Huang; Raquel Vega; De-Hua Yu; Christian G Nelson; Brendan M Smith; Robert Terry; Alicia S Linford; Yang Yu; Gung-wei Chirn; Chuanzheng Song; Mark A Labow; Dalia Cohen; Frederick J King; Eric C Peters; Peter G Schultz; Peter K Vogt; John B Hogenesch; Jeremy S Caldwell
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-26       Impact factor: 11.205

3.  An additional long-term mechanism of NF-κB regulation after cytokine treatment in a human hepatoma cell line.

Authors:  Patricia Kohlhof
Journal:  Virchows Arch       Date:  2010-09-23       Impact factor: 4.064

4.  Genome-wide siRNA screen for mediators of NF-κB activation.

Authors:  Benjamin E Gewurz; Fadi Towfic; Jessica C Mar; Nicholas P Shinners; Kaoru Takasaki; Bo Zhao; Ellen D Cahir-McFarland; John Quackenbush; Ramnik J Xavier; Elliott Kieff
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-17       Impact factor: 11.205

5.  Virus-activated interferon regulatory factor 7 upregulates expression of the interferon-regulated BST2 gene independently of interferon signaling.

Authors:  Mariana G Bego; Johanne Mercier; Eric A Cohen
Journal:  J Virol       Date:  2012-02-01       Impact factor: 5.103

6.  ATP1B3 Protein Modulates the Restriction of HIV-1 Production and Nuclear Factor κ Light Chain Enhancer of Activated B Cells (NF-κB) Activation by BST-2.

Authors:  Hironori Nishitsuji; Ryuichi Sugiyama; Makoto Abe; Hiroshi Takaku
Journal:  J Biol Chem       Date:  2015-12-22       Impact factor: 5.157

7.  Viral and therapeutic control of IFN-beta promoter stimulator 1 during hepatitis C virus infection.

Authors:  Yueh-Ming Loo; David M Owen; Kui Li; Andrea K Erickson; Cynthia L Johnson; Penny M Fish; D Spencer Carney; Ting Wang; Hisashi Ishida; Mitsutoshi Yoneyama; Takashi Fujita; Takeshi Saito; William M Lee; Curt H Hagedorn; Daryl T-Y Lau; Steven A Weinman; Stanley M Lemon; Michael Gale
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-03       Impact factor: 11.205

Review 8.  Tetherin/BST-2: Restriction Factor or Immunomodulator?

Authors:  Sam X Li; Bradley S Barrett; Kejun Guo; Mario L Santiago
Journal:  Curr HIV Res       Date:  2016       Impact factor: 1.581

9.  Identification of mutations in TRAPPC9, which encodes the NIK- and IKK-beta-binding protein, in nonsyndromic autosomal-recessive mental retardation.

Authors:  Asif Mir; Liana Kaufman; Abdul Noor; Mahdi M Motazacker; Talal Jamil; Matloob Azam; Kimia Kahrizi; Muhammad Arshad Rafiq; Rosanna Weksberg; Tanveer Nasr; Farooq Naeem; Andreas Tzschach; Andreas W Kuss; Gisele E Ishak; Dan Doherty; H Hilger Ropers; A James Barkovich; Hossein Najmabadi; Muhammad Ayub; John B Vincent
Journal:  Am J Hum Genet       Date:  2009-12       Impact factor: 11.025

10.  A truncating mutation of TRAPPC9 is associated with autosomal-recessive intellectual disability and postnatal microcephaly.

Authors:  Ganeshwaran H Mochida; Muhammad Mahajnah; Anthony D Hill; Lina Basel-Vanagaite; Danielle Gleason; R Sean Hill; Adria Bodell; Moira Crosier; Rachel Straussberg; Christopher A Walsh
Journal:  Am J Hum Genet       Date:  2009-12       Impact factor: 11.025

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.